Payment overview · 2025
General Payments
$1,107.68
48 reported records · 17 companies
Healthcare provider profile · identity verified
Marc S Coan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOCCOA, GA · NPI 1174516330
Verified facts
What the public records show
CMS Open Payments records show Marc S Coan, MD received $1,107.68 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $311.49 | 28.1% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $139.37 | 12.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.58 | 7.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.66 | 7.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.30 | 5.8% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $62.59 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.37 | 5.5% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $60.42 | 5.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.12 | 5.3% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $36.25 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.04 | 3.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.14 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.49 | 1.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.44 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.69 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.79 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.94 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,107.68 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $293.94 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $139.37 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.58 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.66 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $62.59 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.37 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $60.42 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.42 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $36.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $6.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 763 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 592 | 123 |
| Losartan Potassium | Losartan Potassium | 372 | 99 |
| Ezetimibe | Ezetimibe | 365 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 363 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 100 |
| Tramadol Hcl | Tramadol Hcl | 291 | 62 |
| Simvastatin | Simvastatin | 249 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 47 |
| Gabapentin | Gabapentin | 212 | 46 |
| Lisinopril | Lisinopril | 203 | 57 |
| Montelukast Sodium | Montelukast Sodium | 197 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 191 | 48 |
| Eliquis | Apixaban | 164 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 50 |
| Allopurinol | Allopurinol | 160 | 39 |
| Alprazolam | Alprazolam | 158 | 26 |
| Potassium Chloride | Potassium Chloride | 148 | 43 |
| Metformin Hcl Er | Metformin Hcl | 145 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 139 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 33 |
| Metformin Hcl | Metformin Hcl | 121 | 31 |
| Famotidine | Famotidine | 119 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 14 |
| Omeprazole | Omeprazole | 117 | 34 |
| Mounjaro | Tirzepatide | 111 | 21 |
| Sertraline Hcl | Sertraline Hcl | 110 | 22 |
| Prednisone | Prednisone | 104 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 22 |
| Jardiance | Empagliflozin | 97 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 34 |
| Trazodone Hcl | Trazodone Hcl | 82 | 21 |
| Memantine Hcl | Memantine Hcl | 81 | 20 |
| Glipizide | Glipizide | 80 | 24 |
| Furosemide | Furosemide | 79 | 37 |
| Tradjenta | Linagliptin | 79 | 14 |
| Meloxicam | Meloxicam | 73 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 53 |
| Finasteride | Finasteride | 70 | 21 |
| Trulicity | Dulaglutide | 70 | 14 |
| Donepezil Hcl | Donepezil Hcl | 68 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 64 | 39 |
| Azithromycin | Azithromycin | 62 | 37 |
| Carvedilol | Carvedilol | 62 | 22 |
| Xarelto | Rivaroxaban | 61 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 28 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Pregabalin | Pregabalin | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 17 |
| Irbesartan | Irbesartan | 55 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 19 |
| Chlorthalidone | Chlorthalidone | 54 | 15 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | 18 |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Torsemide | Torsemide | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Nitroglycerin | Nitroglycerin | 44 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Sucralfate | Sucralfate | 42 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Ozempic | Semaglutide | 41 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 12 |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Klor-Con M20 | Potassium Chloride | 37 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 21 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 24 |
| Glipizide Er | Glipizide | 35 | 12 |
| Ramipril | Ramipril | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 20 |
| Atenolol | Atenolol | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Eplerenone | Eplerenone | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Disulfiram | Disulfiram | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,107.68 · 48 records | Amgen Inc. | Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, SUBLOCADE, TARPEYO, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error